Back

Investigating the influence of possible liver fibrosis on mortality in patients with coronary artery disease - a post-hoc ISCHEMIA trial analysis

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Identification and risk stratification of relevant coronary artery disease in clinical practice Chronic Ischaemia ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Tulio Caldonazo

University hospital Jena, Jena (Germany)

3 More presentations in this session

Presentation thumbnail
State-of-the-art lecture on identification and risk stratification of relevant coronary artery disease in clinical practice
Professor P. Steg (Paris, FR)
Slides Video
Presentation thumbnail
Icosapent ethyl by baseline small dense low-density lipoprotein cholesterol: an analysis of REDUCE-IT
Doctor R. Aggarwal (Boston, US)
Abstract Slides Video
Presentation thumbnail
Electrocardiogram-based artificial intelligence to identify prevalent coronary artery disease
Doctor S. Kany (Hamburg, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Identification and risk stratification of relevant coronary artery disease in clinical practice
Video

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Association of liver dysfunction with outcomes after percutaneous coronary intervention - a systematic review and meta-analysis
thumbnail
Congress Presentation
Liver fibrosis and poor outcome in patients with heart failure: new insights from the BIOSTAT-CHF study
thumbnail
Congress Presentation
Profiles of patients with cardiovascular risk factors and the severity of hepatic steatosis and fibrosis assessed by pulsed ultrasound

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources